(Unaudited data)
- DEVELOPMENT OF BUSINESS IN THE THIRD QUARTER (VARIATION AT CURRENT RATE)
thousands of euros | 1st quarter | 2nd quarter | 3rd quarter | ||||||
2015 | 2016 | Var. 16/15 | 2015 | 2016 | Var. 16/15 | 2015 | 2016 | Var. 16/15 |
|
France | 89,584 | 90,494 | +1.0% | 76,864 | 80,469 | +4.7% | 97,767 | 98,840 | +1.1% |
Europe (excluding France) | 40,657 | 43,685 | +7.4% | 29,943 | 31,572 | +5.4% | 50,614 | 41,273 | -18.5% |
North America | 17,193 | 16,064 | -6.6% | 12,894 | 14,113 | +9.5% | 16,055 | 16,020 | -0.2% |
Other countries | 4,622 | 3,846 | -16.8% | 3,816 | 4,061 | +6.4% | 3,594 | 3,280 | -8.7% |
Group total | 152,056 | 154,089 | +1.3% | 123,517 | 130,215 | +5.4% | 168,030 | 159,413 | -5.1% |
thousands of euros | 1st quarter | 2nd quarter | 3rd quarter | ||||||
2015 | 2016 | Var. 16/15 | 2015 | 2016 | Var. 16/15 | 2015 | 2016 | Var. 16/15 |
|
Non-proprietary Homeopathic Medicines | 79,191 | 80,147 | +1.2% | 74,354 | 76,001 | +2.2% | 73,677 | 73,913 | +0.3% |
OTC Specialties | 72,880 | 73,743 | +1.2% | 49,030 | 53,719 | +9.6% | 94,328 | 85,319 | -9.6% |
Other | -15 | 199 | - | 133 | 495 | +272.2% | 25 | 181 | +624.0% |
Group total | 152,056 | 154,089 | +1.3% | 123,517 | 130,215 | +5.4% | 168,030 | 159,413 | -5.1% |
- CUMULATIVE ACTIVITY AS OF THE END OF SEPTEMBER 2016
thousands of euros | 2015 | 2016 | Variation at current exchange rates | Variation at constant exchange rates |
France | 264,215 | 269,803 | +2.1% | +2.1% |
Europe (excluding France) | 121,214 | 116,530 | -3.9% | -1.0% |
North America | 46,142 | 46,197 | +0.1% | +0.9% |
Other countries | 12,032 | 11,187 | -7.0% | -4.3% |
Group total | 443,603 | 443,717 | +0.0% | +1.0% |
thousands of euros | 2015 | 2016 | Variation at current exchange rates | Variation at constant exchange rates |
Non-proprietary Homeopathic Medicines | 227,222 | 230,061 | +1.2% | +1.3% |
OTC Specialties | 216,238 | 212,781 | -1.6% | +0.3% |
Other | 143 | 875 | +511.9% | +511.9% |
Group total | 443,603 | 443,717 | +0.0% | +1.0% |
- HIGHLIGHTS OF THE THIRD QUARTER
- Sales revenue in the third quarter of 2016 was down by 5.1% in comparison to 2015 (the impact of exchange rates is not significant over the period).
- Sales are decreasing significantly in Russia and to a lesser extent in Spain and in the Czech Republic. They are increasing in France.
- OUTLOOK
- The level of activity and profitability of the fiscal year will depend on the seasonal pathology of the fourth quarter.
- Our company still continues with the same determination the development of homeopathy in the world.
Our next update: January 26, 2017 at market close, publication of the sales revenue for the year 2016.
Person responsible for FINANCIAL information: Christian Boiron
Contact for financial information: Véronique Bouscayrol
Investor relations: +33 (0) 4.78.45.63.43 - e-mail : boironfinances@boiron.fr
ISIN Code: FR0000061129 (BOI) - Bloomberg: BOI FP - Reuters: BOIR.PA
The group's financial information is online at: www.boironfinance.com